Cephalon Drops Patent Suit Vs. Sandoz Over Provigil

Law360, New York (May 3, 2005, 12:00 AM EDT) -- Cephalon, Inc. has dropped its patent infringement suit against Swiss drug maker Sandoz following that drugmaker's decision not to market a generic version of Cephalon's drug Provigil.

According to Cephalon, Sandoz has decided not to challenge Cephalon's patent position on Provigil, a treatment for excessive day-time sleepiness. Instead, Sandoz will wait until 2014 to seek to put out a generic version of the drug, when a patent on one of Provigil's key ingredients is set to expire.

Instead, Sandoz plans to convert its abbreviated new drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.